EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study

Christopher G Bunick iD, Joyce M C Teng, Scott Guenthner, Kalyani Marathe, Steven Kempers, Kimmie Eads, Leslie Castelo-Soccio, Alan M Mendelsohn, Jessica Raiz, Dédée F Murrell iD

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad105 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Christopher G Bunick und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Isotretinoin, Ichthyosis, Lamellar. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Timber Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emollients and keratolytics are frequently used to manage symptoms of congenital ichthyosis (CI). Systemic retinoid treatment is complicated by teratogenicity and dose-limiting adverse effects.

Objectives

This analysis from the randomized Phase IIb CONTROL study investigated the characteristics of participants who responded to treatment with TMB-001, a novel topical isotretinoin ointment formulation.

Methods

Participants ≥ 9 years of age with genetically confirmed CI and ≥ 2 (out of 4) Visual Index for Ichthyosis Severity (VIIS) assessment areas with ≥ 3 scaling score were randomized 1 : 1 : 1 to TMB-001 0.05%, TMB-001 0.1% or vehicle, twice daily for 12 weeks. Efficacy endpoints included the proportion of participants with ≥ 50% reduction in VIIS-scaling (VIIS-50) compared with baseline and ≥ 2-grade reduction in Investigator's Global Assessment (IGA)-scaling score compared with baseline. Changes in body surface area (BSA) involvement, Dermatology Life Quality Index (DLQI) scores and Itch-Numeric Rating Scale (I-NRS) scores were assessed.

Results

Among the 33 participants (11 randomized to TMB-001 0.05%, 10 to TMB-001 0.1% and 12 to vehicle), median age was 29 years (range 9–80), and most were male (64%) and White (79%). Baseline demographics were generally similar among participants who did or did not achieve TMB-001 treatment success. Participants who had lower mean BSA involvement and higher DLQI and I-NRS scores at baseline were more likely to achieve VIIS-50. Similarly, higher baseline DLQI and I-NRS scores were associated with IGA response; BSA involvement was similar for IGA responders vs. nonresponders.

Conclusions

Higher DLQI and I-NRS scores at baseline were associated with participants achieving treatment success by VIIS-50 and IGA response. Lower BSA involvement was associated with VIIS-50 success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsotretinoinIchthyosis, LamellarHumansMaleChildAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overInfant, NewbornFemaleEmollientsTreatment OutcomePruritusImmunoglobulin ASeverity of Illness IndexDouble-Blind Method

Substanzen

IsotretinoinEmollientsImmunoglobulin A

Autor:innen und Institutionen

  • Yale University School of Medicine, New Haven, CT, USA.
  • Stanford School of Medicine, Stanford University, Palo Alto, CA, USA.
  • The Dermatology Center of Indiana, Plainfield, IN, USA.
  • The Indiana Clinical Trials Center, PC, Plainfield, IN, USA.
  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Associated Skin Care Specialists, New Brighton, MN, USA.

ORCID-Profile: Christopher G Bunick, Dédée F Murrell

Förderung

  • Timber Pharmaceuticals

Zitieren

APA

Bunick, C. G., Teng, J. M. C., Guenthner, S., Marathe, K., Kempers, S., Eads, K., Castelo-Soccio, L., Mendelsohn, A. M., Raiz, J., & Murrell, D. F. (2023). Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad105

Vancouver

Bunick CG, Teng JMC, Guenthner S, Marathe K, Kempers S, Eads K, et al. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad105

BibTeX
@article{Bunick2023,
  author = {Bunick, Christopher G and Teng, Joyce M C and Guenthner, Scott and Marathe, Kalyani and Kempers, Steven and Eads, Kimmie and Castelo-Soccio, Leslie and Mendelsohn, Alan M and Raiz, Jessica and Murrell, Dédée F},
  title = {Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad105}
}
Kostenlos starten →